Skip to main content

Resultados relacionados

Resultados totales (Incluyendo duplicados): 10
Encontrada(s) 1 página(s)

RiuNet. Repositorio Institucional de la Universitat Politécnica de Valéncia
Publication Artículo científico (JournalArticle)

Mapping and identification of antifungal peptides in the putative antifungal protein AfpB from the filamentous fungus Penicillium digitatum

  • Garrigues, Sandra
  • Gandía, Mónica
  • Borics, Attila
  • Marx, Florentine
  • Manzanares, Paloma
  • Marcos, Jose F.
[EN] Antifungal proteins (AFPs) from Ascomycetes are small cysteine-rich proteins that are abundantly secreted and show antifungal activity against non-producer fungi. A gene coding for a class B AFP (AfpB) was previously identified in the genome of the plant pathogen Penicillium digitatum. However, previous attempts to detect the AfpB protein were not successful despite the high expression of the corresponding afpB gene. In this work, the structure of the putative AfpB was modeled. Based on this model, four synthetic cysteine-containing peptides, PAF109, PAF112, PAF118, and PAF119, were designed and their antimicrobial activity was tested and characterized. PAF109 that corresponds to the ¿-core motif present in defensin-like antimicrobial proteins did not show antimicrobial activity. On the contrary, PAF112 and PAF118, which are cationic peptides derived from two surface-exposed loops in AfpB, showed moderate antifungal activity against P. digitatum and other filamentous fungi. It was also confirmed that cyclization through a disulfide bridge prevented peptide degradation. PAF116, which is a peptide analogous to PAF112 but derived from the Penicillium chrysogenum antifungal protein PAF, showed activity against P. digitatum similar to PAF112, but was less active than the native PAF protein. The two AfpB-derived antifungal peptides PAF112 and PAF118 showed positive synergistic interaction when combined against P. digitatum. Furthermore, the synthetic hexapeptide PAF26 previously described in our laboratory also exhibited synergistic interaction with the peptides PAF112, PAF118, and PAF116, as well as with the PAF protein. This study is an important contribution to the mapping of antifungal motifs within the AfpB and other AFPs, and opens up new strategies for the rational design and application of antifungal peptides and proteins., This work was funded by grants BIO2012-34381 and BIO2015-68790-C2-1-R from the Ministerio de Economía y Competitividad (Spain) (MINECO/FEDER Funds) and P25894-B20 from the Austrian Science Fund (FWF). SG was recipient of a predoctoral scholarship (FPU13/04584) within the FPU program from Ministerio de Educación, Cultura y Deporte (MECD, Spain). Support for publication was provided by the CSIC Open Access Publication Support Initiative through its Unit of Information Resources for Research (URICI).
RiuNet. Repositorio Institucional de la Universitat Politécnica de Valéncia
Publication Artículo científico (JournalArticle)

A Parallel Structured Divide-and-Conquer Algorithm for Symmetric Tridiagonal Eigenvalue Problems

  • Liao, Xia
  • Li, Shengguo
  • Lu, Yutong
  • Jose E. Roman|||0000-0003-1144-6772
[EN] In this article, a parallel structured divide-and-conquer (PSDC) eigensolver is proposed for symmetric tridiagonal matrices based on ScaLAPACK and a parallel structured matrix multiplication algorithm, called PSMMA. Computing the eigenvectors via matrix-matrix multiplications is the most computationally expensive part of the divide-and-conquer algorithm, and one of the matrices involved in such multiplications is a rank-structured Cauchy-like matrix. By exploiting this particular property, PSMMA constructs the local matrices by using generators of Cauchy-like matrices without any communication, and further reduces the computation costs by using a structured low-rank approximation algorithm. Thus, both the communication and computation costs are reduced. Experimental results show that both PSMMA and PSDC are highly scalable and scale to 4096 processes at least. PSDC has better scalability than PHDC that was proposed in [16] and only scaled to 300 processes for the same matrices. Comparing with PDSTEDC in ScaLAPACK, PSDC is always faster and achieves 1.4x-1.6x speedup for some matrices with few deflations. PSDC is also comparable with ELPA, with PSDC being faster than ELPA when using few processes and a little slower when using many processes., The authors would like to thank the referees for their valuable comments which greatly improve the presentation of this article. This work was supported by National Natural Science Foundation of China (No. NNW2019ZT6-B20, NNW2019ZT6B21, NNW2019ZT5-A10, U1611261, 61872392, and U1811461), National Key RD Program of China (2018YFB0204303), NSF of Hunan (No. 2019JJ40339), NSF of NUDT (No. ZK18-03-01), Guangdong Natural Science Foundation (2018B030312002), and the Program for Guangdong Introducing Innovative and Entrepreneurial Teams under Grant 2016ZT06D211. The work of Jose E. Roman was supported by the Spanish Agencia Estatal de Investigacion (AEI) under project SLEPc-DA (PID2019-107379RB-I00).
RiuNet. Repositorio Institucional de la Universitat Politécnica de Valéncia
Publication Artículo científico (JournalArticle)

Transient glyco-engineering to produce recombinant IgA1 with defined N-and O-glycans in plants

  • Dicker, Martina
  • Tschofen, Marc
  • Maresch, Daniel
  • Koenig, Julia
  • Juarez, Paloma
  • Altmann, Friedrich
  • Steinkellner, Herta
  • Strasser, Richard
  • Orzáez Calatayud, Diego Vicente
[EN] The production of therapeutic antibodies to combat pathogens and treat diseases, such as cancer is of great interest for the biotechnology industry. The recent development of plant-based expression systems has demonstrated that plants are well-suited for the production of recombinant monoclonal antibodies with defined glycosylation. Compared to immunoglobulin G (IgG), less effort has been undertaken to express immunoglobulin A (IgA), which is the most prevalent antibody class at mucosal sites and a promising candidate for novel recombinant biopharmaceuticals with enhanced anti-tumor activity. Here, we transiently expressed recombinant human IgA1 against the VP8* rotavirus antigen in glyco-engineered XT/FT Nicotiana benthamiana plants. Mass spectrometric analysis of IgA1 glycopeptides revealed the presence of complex biantennary N-glycans with terminal N-acetylglucosamine present on the N-glycosylation site of the CH2 domain in the IgA1 alpha chain. Analysis of the peptide carrying nine potential O-glycosylation sites in the IgA1 alpha chain hinge region showed the presence of plant-specific modifications including hydroxyproline formation and the attachment of pentoses. By co-expression of enzymes required for initiation and elongation of human O-glycosylation it was possible to generate disialylated mucin-type core 1 O-glycans on plant-produced IgA1. Our data demonstrate that XT/FT N. benthamiana plants can be engineered toward the production of recombinant IgA1 with defined human-type Nand O-linked glycans., This work was supported by a grant from the Austrian Federal Ministry of Transport, Innovation and Technology (bmvit) and Austrian Science Fund (FWF): TRP 242-B20 and by the Austrian Research Promotion Agency (Laura Bassi Center of Expertise "Plant produced Bio-Pharmaceuticals" Grant Nr. 822757).
Zaguán. Repositorio Digital de la Universidad de Zaragoza
Publication Artículo científico (JournalArticle)

Identification and Functional Characterization of Two Intronic NIPBL Mutations in Two Patients with Cornelia de Lange Syndrome

  • Teresa-Rodrigo, M.
  • Eckhold, J.
  • Puisac, B.
  • Pozojevic, J.
  • Parenti, I.
  • Baquero-Montoya, C.
  • Gil-Rodríguez, M.C.
  • Braunholz, D.
  • Dalski, A.
  • Hernández-Marcos, M.
  • Ayerza, A.
  • Bernal, M.L.
  • Ramos, F.J.
  • Wieczorek, D.
  • Gillessen-Kaesbach, G.
  • Pié, J.
  • Kaiser, F.J.
Cornelia de Lange syndrome (CdLS) is a rare genetically heterogeneous disorder with a high phenotypic variability including mental retardation, developmental delay, and limb malformations. The genetic causes in about 30% of patients with CdLS are still unknown. We report on the functional characterization of two intronic NIPBL mutations in two patients with CdLS that do not affect a conserved splice-donor or acceptor site. Interestingly, mRNA analyses showed aberrantly spliced transcripts missing exon 28 or 37, suggesting the loss of the branch site by the c.5329-15A>G transition and a disruption of the polypyrimidine by the c.6344del(-13)-(-8) deletion. While the loss of exon 28 retains the reading frame of the NIBPL transcript resulting in a shortened protein, the loss of exon 37 shifts the reading frame with the consequence of a premature stop of translation. Subsequent quantitative PCR analysis demonstrated a 30% decrease of the total NIPBL mRNA levels associated with the frameshift transcript. Consistent with our results, this patient shows a more severe phenotype compared to the patient with the aberrant transcript that retains its reading frame. Thus, intronic variants identified by sequencing analysis in CdLS diagnostics should carefully be examined before excluding them as nonrelevant to disease.
Zaguán. Repositorio Digital de la Universidad de Zaragoza
Publication Artículo científico (JournalArticle)

Functional characterization of NIPBL physiological splice variants and eight splicing mutations in patients with cornelia de lange syndrome

  • Teresa-Rodrigo, M.
  • Eckhold, J.
  • Puisac, B.
  • Dalski, A.
  • Gil-Rodríguez, M.C.
  • Braunholz, D.
  • Baquero, C.
  • Hernández-Marcos, M.
  • de Karam, J.C.
  • Ciero, M.
  • Santos-Simarro, F.
  • Lapunzina, P.
  • Wierzba, J.
  • Casale, C.H.
  • Ramos, F.J.
  • Gillessen-Kaesbach, G.
  • Kaiser, F.J.
  • Pié, J.
Cornelia de Lange syndrome (CdLS) is a congenital developmental disorder characterized by distinctive craniofacial features, growth retardation, cognitive impairment, limb defects, hirsutism, and multisystem involvement. Mutations in five genes encoding structural components (SMC1A, SMC3, RAD21) or functionally associated factors (NIPBL, HDAC8) of the cohesin complex have been found in patients with CdLS. In about 60% of the patients, mutations in NIPBL could be identified. Interestingly, 17% of them are predicted to change normal splicing, however, detailed molecular investigations are often missing. Here, we report the first systematic study of the physiological splicing of the NIPBL gene, that would reveal the identification of four new splicing isoforms ¿E10, ¿E12, ¿E33,34, and B’. Furthermore, we have investigated nine mutations affecting splice-sites in the NIPBL gene identified in twelve CdLS patients. All mutations have been examined on the DNA and RNA level, as well as by in silico analyses. Although patients with mutations affecting NIPBL splicing show a broad clinical variability, the more severe phenotypes seem to be associated with aberrant transcripts resulting in a shift of the reading frame.
Zaguán. Repositorio Digital de la Universidad de Zaragoza
Publication Artículo científico (JournalArticle)

mRNA quantification of NIPBL isoforms A and B in adult and fetal human tissues, and a potentially pathological variant affecting only isoform a in two patients with Cornelia de Lange syndrome

  • Puisac, B.
  • Teresa-Rodrigo, M.
  • Hernández-Marcos, M.
  • Baquero-Montoya, C.
  • Gil-Rodríguez, M.C
  • Visnes, T.
  • Bot, C.
  • Gómez-Puertas, P.
  • Kaiser, F.J.
  • Ramos, F.J.
  • Ström, L.
  • Pié, J.
Cornelia de Lange syndrome (CdLS) is a congenital developmental disorder characterized by craniofacial dysmorphia, growth retardation, limb malformations, and intellectual disability. Approximately 60% of patients with CdLS carry a recognizable pathological variant in the NIPBL gene, of which two isoforms, A and B, have been identified, and which only differ in the C-terminal segment. In this work, we describe the distribution pattern of the isoforms A and B mRNAs in tissues of adult and fetal origin, by qPCR (quantitative polymerase chain reaction). Our results show a higher gene expression of the isoform A, even though both seem to have the same tissue distribution. Interestingly, the expression in fetal tissues is higher than that of adults, especially in brain and skeletal muscle. Curiously, the study of fibroblasts of two siblings with a mild CdLS phenotype and a pathological variant specific of the isoform A of NIPBL (c.8387A > G; P.Tyr2796Cys), showed a similar reduction in both isoforms, and a normal sensitivity to DNA damage. Overall, these results suggest that the position of the pathological variant at the 3´ end of the NIPBL gene affecting only isoform A, is likely to be the cause of the atypical mild phenotype of the two brothers.
Zaguán. Repositorio Digital de la Universidad de Zaragoza
Publication Artículo científico (JournalArticle)

Two-step ATP-driven opening of cohesin head

  • Marcos-Alcalde, Í.
  • Mendieta-Moreno, J.I.
  • Puisac, B.
  • Gil-Rodríguez, M.C.
  • Hernández-Marcos, M.
  • Soler-Polo, D.
  • Ramos, F.J.
  • Ortega, J.
  • Pié, J.
  • Mendieta, J.
  • Gómez-Puertas, P.
The cohesin ring is a protein complex composed of four core subunits: Smc1A, Smc3, Rad21 and Stag1/2. It is involved in chromosome segregation, DNA repair, chromatin organization and transcription regulation. Opening of the ring occurs at the "head" structure, formed of the ATPase domains of Smc1A and Smc3 and Rad21. We investigate the mechanisms of the cohesin ring opening using techniques of free molecular dynamics (MD), steered MD and quantum mechanics/molecular mechanics MD (QM/MM MD). The study allows the thorough analysis of the opening events at the atomic scale: I) ATP hydrolysis at the Smc1A site, evaluating the role of the carboxy-terminal domain of Rad21 in the process; ii) the activation of the Smc3 site potentially mediated by the movement of specific amino acids; and iii) opening of the head domains after the two ATP hydrolysis events. Our study suggests that the cohesin ring opening is triggered by a sequential activation of the ATP sites in which ATP hydrolysis at the Smc1A site induces ATPase activity at the Smc3 site. Our analysis also provides an explanation for the effect of pathogenic variants related to cohesinopathies and cancer.
Zaguán. Repositorio Digital de la Universidad de Zaragoza
Publication Artículo científico (JournalArticle)

Human mitochondrial HMG-CoA synthase deficiency: Role of enzyme dimerization surface and characterization of three new patients

  • Puisac, B.
  • Marcos-Alcalde, I.
  • Hernández-Marcos, M./Tobajas Morlana, P.
  • Levtova, A.
  • Schwahn, B.C.
  • Delaet, C.
  • Lace, B.
  • Gómez-Puertas, P.
  • Pié, J.
Mitochondrial 3-hydroxy-3-methylglutaryl-CoA synthase deficiency (mitochondrial HMG-CoA synthase deficiency or mHS deficiency, OMIM #605911) is an inborn error of metabolism that affects ketone body synthesis. Acute episodes include vomiting, lethargy, hepatomegaly, hypoglycemia and dicarboxylic aciduria. The diagnosis is difficult due to the relatively unspecific clinical and biochemical presentation, and fewer than 30 patients have been described. This work describes three new patients with mHS deficiency and two missense mutations c.334C>T (p.R112W) and c.430G>T (p.V144L) previously not reported. We developed a new method to express and measure the activity of the enzyme and in this work the study is extended to ten new missense variants including those of our patients. Enzymatic assays showed that three of the mutant proteins retained some but seven completely lacked activity. The identification of a patient homozygous for a mutation that retains 70% of enzyme activity opens the door to a new interpretation of the disease by demonstrating that a modest impairment of enzyme function can actually produce symptoms. This is also the first study employing molecular dynamics modelling of the enzyme mutations. We show that the correct maintenance of the dimerization surface is crucial for retaining the structure of the active center and therefore the activity of the enzyme.
Zaguán. Repositorio Digital de la Universidad de Zaragoza
Publication Artículo científico (JournalArticle)

Phenotypes and genotypes in individuals with SMC1A variants

  • Huisman, S.
  • Mulder, P.A.
  • Redeker, E.
  • Bader, I.
  • Bisgaard, A.-M.
  • Brooks, A.
  • Cereda, A.
  • Cinca, C.
  • Clark, D.
  • Cormier-Daire, V.
  • Deardorff, M.A.
  • Diderich, K.
  • Elting, M.
  • van Essen, A.
  • FitzPatrick , D.
  • Gervasini, C.
  • Gillessen-Kaesbach, G.
  • Girisha, K.M.
  • Hilhorst-Hofstee, Y.
  • Hopman, S.
  • Horn, D.
  • Isrie, M.
  • Jansen, S.
  • Jespersgaard, C.
  • Kaiser, F.J.
  • Kaur, M.
  • Kleefstra, T.
  • Krantz, I.D.
  • Lakeman, P.
  • Landlust, A.
  • Lessel, D.
  • Michot, C.
  • Moss, J.
  • Noon, S.E.
  • Oliver, C.
  • Parenti, I.
  • Pie, J.
  • Ramos, F.J.
  • Rieubland, C.
  • Russo, S.
  • Selicorni, A.
  • Tümer, Z.
  • Vorstenbosch, R.
  • Wenger, T.L.
  • van Balkom, I.
  • Piening, S.
  • Wierzba, J.
  • Hennekam, R.C.
SMC1A encodes one of the proteins of the cohesin complex. SMC1A variants are known to cause a phenotype resembling Cornelia de Lange syndrome (CdLS). Exome sequencing has allowed recognizing SMC1A variants in individuals with encephalopathy with epilepsy who do not resemble CdLS. We performed an international, interdisciplinary study on 51 individuals with SMC1A variants for physical and behavioral characteristics, and compare results to those in 67 individuals with NIPBL variants. For the Netherlands all known individuals with SMC1A variants were studied, both with and without CdLS phenotype. Individuals with SMC1A variants can resemble CdLS, but manifestations are less marked compared to individuals with NIPBL variants: growth is less disturbed, facial signs are less marked (except for periocular signs and thin upper vermillion), there are no major limb anomalies, and they have a higher level of cognitive and adaptive functioning. Self-injurious behavior is more frequent and more severe in the NIPBL group. In the Dutch group 5 of 13 individuals (all females) had a phenotype that shows a remarkable resemblance to Rett syndrome: epileptic encephalopathy, severe or profound intellectual disability, stereotypic movements, and (in some) regression. Their missense, nonsense, and frameshift mutations are evenly spread over the gene. We conclude that SMC1A variants can result in a phenotype resembling CdLS and a phenotype resembling Rett syndrome. Resemblances between the SMC1A group and the NIPBL group suggest that a disturbed cohesin function contributes to the phenotype, but differences between these groups may also be explained by other underlying mechanisms such as moonlighting of the cohesin genes.
Zaguán. Repositorio Digital de la Universidad de Zaragoza
Publication Reseña (Review)

Diagnosis and management of Cornelia de Lange syndrome: first international consensus statement

  • Kline, A.D.
  • Moss, J.F.
  • Selicorni, A.
  • Bisgaard, A.M.
  • Deardorff, M.A.
  • Gillett, P.M.
  • Ishman, S.L.
  • Kerr, L.M.
  • Levin, A.V.
  • Mulder, P.A.
  • Ramos, F.J.
  • Wierzba, Jl
  • Ajmone, P.F.
  • Axtell, D.
  • Blagowidow, N.
  • Cereda, A.
  • Costantino, A.
  • Cormier-Daire, V.
  • FitzPatrick, D.
  • Grados, M.
  • Groves, L.
  • Guthrie, W.
  • Huisman, S.
  • Kaiser, F.J.
  • Koekkoek, G.
  • Levis, M.
  • Mariani, M.
  • McCleery, J.P.
  • Menke, L.A.
  • Metrena, A
  • O'Connor, J.
  • Oliver, C.
  • Pie, J.
  • Piening, S.
  • Potter, C.J.
  • Quaglio, A.L.
  • Redeker, E.
  • Richman, D.
  • Rigamonti, C.
  • Shi, A.
  • Tümer, Z.
  • Van Balkom, I.D.C.
  • Hennekam, R.C.
Cornelia de Lange syndrome (CdLS) is an archetypical genetic syndrome that is characterized by intellectual disability, well-defined facial features, upper limb anomalies and atypical growth, among numerous other signs and symptoms. It is caused by variants in any one of seven genes, all of which have a structural or regulatory function in the cohesin complex. Although recent advances in next-generation sequencing have improved molecular diagnostics, marked heterogeneity exists in clinical and molecular diagnostic approaches and care practices worldwide. Here, we outline a series of recommendations that document the consensus of a group of international experts on clinical diagnostic criteria, both for classic CdLS and non-classic CdLS phenotypes, molecular investigations, long-term management and care planning.